{"title":"The frequency of fibromyalgia in patients with systemic lupus erythematosus and associated factors: a systematic review and meta-analysis.","authors":"Sohi Mistry, Ansaam Daoud, Marina Nighat Magrey, Omer Nuri Pamuk","doi":"10.1007/s10067-024-07188-9","DOIUrl":null,"url":null,"abstract":"<p><p>Fibromyalgia (FM) in systemic lupus erythematosus (SLE) patients contributes to increased fatigue, anxiety, depression, and mental exhaustion. This study's objective is to systematically review the literature and to determine the frequency of FM in patients with SLE and its associated factors. A literature review was conducted to assess the prevalence of FM in SLE patients and to identify FM-associated factors. This involved searching the PubMed and Cochrane Library databases from 1959 to 2023. Cohorts, case-control, and population-based studies were included, while those not focusing on FM rates in SLE patients were excluded. Data on FM-associated factors and FM frequency in control or connective tissue disease (CTD) groups were obtained if available. Secondary analyses compared FM frequencies in SLE and other groups (healthy controls or CTD groups). Fifty-six studies met the eligibility criteria. Out of the 56 studies, nine included comparative data between SLE patients and healthy controls, while six presented data comparing the frequency of FM in patients with SLE and other CTDs. The combined cohorts included 58,052 SLE patients. Among 5063 SLE patients, FM was detected. The overall random-effects pooled prevalence of FM was 15.8% (95% CI, 13.4-18.5) with high heterogeneity (I<sup>2</sup>, 97.9%). Our analysis revealed a significantly higher risk of FM in patients with SLE compared to controls (OR, 3.7; 95% CI, 2.74-5.0). There was a higher risk of FM in SLE patients compared to other rheumatic diseases, but the difference was not significant. Our study showed that the prevalence of FM is higher in patients with SLE compared to the general population. FM in SLE may act as a confounding factor when assessing disease activity and treatment response. Research results indicate that concurrent FM is a frequent comorbidity in SLE, emphasizing the importance of recognizing its occurrence in SLE patients.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10067-024-07188-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Fibromyalgia (FM) in systemic lupus erythematosus (SLE) patients contributes to increased fatigue, anxiety, depression, and mental exhaustion. This study's objective is to systematically review the literature and to determine the frequency of FM in patients with SLE and its associated factors. A literature review was conducted to assess the prevalence of FM in SLE patients and to identify FM-associated factors. This involved searching the PubMed and Cochrane Library databases from 1959 to 2023. Cohorts, case-control, and population-based studies were included, while those not focusing on FM rates in SLE patients were excluded. Data on FM-associated factors and FM frequency in control or connective tissue disease (CTD) groups were obtained if available. Secondary analyses compared FM frequencies in SLE and other groups (healthy controls or CTD groups). Fifty-six studies met the eligibility criteria. Out of the 56 studies, nine included comparative data between SLE patients and healthy controls, while six presented data comparing the frequency of FM in patients with SLE and other CTDs. The combined cohorts included 58,052 SLE patients. Among 5063 SLE patients, FM was detected. The overall random-effects pooled prevalence of FM was 15.8% (95% CI, 13.4-18.5) with high heterogeneity (I2, 97.9%). Our analysis revealed a significantly higher risk of FM in patients with SLE compared to controls (OR, 3.7; 95% CI, 2.74-5.0). There was a higher risk of FM in SLE patients compared to other rheumatic diseases, but the difference was not significant. Our study showed that the prevalence of FM is higher in patients with SLE compared to the general population. FM in SLE may act as a confounding factor when assessing disease activity and treatment response. Research results indicate that concurrent FM is a frequent comorbidity in SLE, emphasizing the importance of recognizing its occurrence in SLE patients.
系统性红斑狼疮(SLE)患者的纤维肌痛(FM)会导致疲劳、焦虑、抑郁和精神疲惫加剧。本研究的目的是系统地回顾文献,确定系统性红斑狼疮患者发生 FM 的频率及其相关因素。为了评估系统性红斑狼疮患者中FM的患病率并确定与FM相关的因素,我们进行了一次文献综述。这项工作包括检索1959年至2023年的PubMed和Cochrane图书馆数据库。其中包括队列研究、病例对照研究和基于人群的研究,但不包括那些不关注系统性红斑狼疮患者FM发生率的研究。如果有 FM 相关因素的数据以及对照组或结缔组织病(CTD)组的 FM 发生率的数据,则予以获取。二次分析比较了系统性红斑狼疮组和其他组(健康对照组或结缔组织病组)的 FM 频率。56项研究符合资格标准。在这 56 项研究中,有 9 项研究提供了系统性红斑狼疮患者与健康对照组之间的比较数据,有 6 项研究提供了系统性红斑狼疮患者与其他 CTD 患者的 FM 频率比较数据。合并的队列包括 58052 名系统性红斑狼疮患者。在 5063 名系统性红斑狼疮患者中,发现了 FM。FM的总体随机效应汇总患病率为15.8%(95% CI,13.4-18.5),异质性很高(I2,97.9%)。我们的分析表明,与对照组相比,系统性红斑狼疮患者发生 FM 的风险明显更高(OR,3.7;95% CI,2.74-5.0)。与其他风湿性疾病相比,系统性红斑狼疮患者患 FM 的风险更高,但差异并不明显。我们的研究表明,与普通人群相比,系统性红斑狼疮患者的FM患病率更高。在评估疾病活动性和治疗反应时,系统性红斑狼疮患者的FM可能是一个混杂因素。研究结果表明,并发 FM 是系统性红斑狼疮的一种常见合并症,这就强调了认识系统性红斑狼疮患者并发 FM 的重要性。
期刊介绍:
Clinical Rheumatology is an international English-language journal devoted to publishing original clinical investigation and research in the general field of rheumatology with accent on clinical aspects at postgraduate level.
The journal succeeds Acta Rheumatologica Belgica, originally founded in 1945 as the official journal of the Belgian Rheumatology Society. Clinical Rheumatology aims to cover all modern trends in clinical and experimental research as well as the management and evaluation of diagnostic and treatment procedures connected with the inflammatory, immunologic, metabolic, genetic and degenerative soft and hard connective tissue diseases.